Beryl drugs Limited has announced a board meeting scheduled for April 1, 2026, to deliberate on several important corporate governance matters. The meeting, set to commence at 11:00 AM at the company's registered office at 133, Kanchan Bagh, Indore 452001, will address key business decisions including director appointments and related party transactions.

Key Agenda Items

The board meeting will focus on eight primary business matters, with the most significant being the consideration and approval of an Extra Ordinary General Meeting (EOGM) notice. The EOGM will address critical appointments and transactions that require shareholder approval.

Director Appointments and Corporate Governance

The proposed EOGM will seek shareholder approval for regularizing Mr. Shailendra Pathak's appointment as Whole Time Director, including fixing his role, obligations, responsibilities, and remuneration. Additionally, the meeting will consider the appointment of Mrs. Neha Sarda as an Independent Director, strengthening the company's board composition.

A significant aspect of the agenda involves approving material related party transactions with M/s. Aminova Infusions P. Ltd., where Mr. Shailendra Pathak holds a directorship with 50% equity stake. This transaction requires proper disclosure and shareholder approval under regulatory requirements.

Administrative and Compliance Matters

The board will address several administrative functions essential for smooth operations. These include fixing the cut-off date and remote e-voting period for the EOGM, appointing Dipika Kataria as scrutinizer for e-voting processes, and authorizing directors to authenticate and file necessary forms under the Companies Act, 2013.

• Appointment of internal auditor for financial year 2026-2027 • General disclosures of directors' interests under section 184(1) • Authority to Mr. Sudhir Sethi for tender-related documentation • Consideration of additional resolutions with chair's permission

Meeting Details and Communication

The formal notice, dated March 20, 2026, was communicated to The Bombay Stock Exchange Limited as required under Regulation 29. Managing Director Sanjay Sethi (DIN: 00090272) signed the official communication, ensuring compliance with stock exchange notification requirements. The company has requested the exchange to take the information on record for further necessary actions.

Beryl Drugs Limited has disclosed another share acquisition by its promoter and director Mr. Sudhir Sethi, who acquired 5,000 shares worth ₹1.01 lakh under SEBI's Insider Trading Regulations. This latest transaction on 16-03-2026 represents 0.09% of the company's total share capital, demonstrating continued promoter confidence in the pharmaceutical company.

Transaction Details and Regulatory Compliance

The acquisition was disclosed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, with the company filing the disclosure on 17-03-2026. Mr. Sudhir Sethi (DIN: 00090172) purchased the shares through market transactions on BSE, with the disclosure submitted to The Bombay Stock Exchange Limited.

Updated Shareholding Pattern

With this latest acquisition, Mr. Sudhir Sethi's stake has increased from 9.33% to 9.42% of the total equity share capital. The disclosure shows his holding increased from 4,73,183 shares to 4,78,183 shares, representing continued commitment to the company's growth prospects.

Promoter Group Structure

The disclosure reveals the complete promoter group structure of Beryl Drugs Limited, which includes four key promoters. The promoter group consists of Sanjay Sethi (Managing Director), Sangita Sethi, Sudhir Sethi, and Soniya Sethi, all holding significant stakes in the pharmaceutical company.

Corporate Structure and Management

Beryl Drugs Limited maintains its registered office at Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.), with CIN L02423MP1993PLC007840. The disclosure was properly submitted by Managing Director Sanjay Sethi (DIN: 00090277) on behalf of the company, ensuring compliance with regulatory requirements for insider trading disclosures. The company's total equity share capital remains at 50,71,700 shares, and it maintains regular communication through beryldrugs25@yahoo.com .